Irinotecan liposoma

Phase 2Small molecule

DDai, Guanghai

Irinotecan liposoma is one of 20 small molecule programs targeting Bevacizumab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BevacizumabRecruiting

BevacizumabPhase 2

Recruiting

Competition

Competitive Landscape

23 competitors in Bevacizumab

#DrugCompanyPhaseTrials

Avastin

Roche

Approved

88 2

Eloxatin

Teva

Phase 3

7 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

3 4

Adrucil

EElorac, Inc.

Phase 3

2 5

Tecentriq

Roche

Phase 2

9 6

Rubraca

Bristol-Myers Squibb

Phase 2

3 7

Opdivo

Bristol-Myers Squibb

Phase 2

2 8

Trodelvy

Gilead

Phase 2

1 9

Lazcluze

Johnson & Johnson

Phase 2

1 10

Lynparza

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Bevacizumab

NCT06782685

Clinical

Trials by Indication[1]

Bevacizumab1 trial

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

Recruiting·DDai, Guanghai·Phase 1/2·NCT06782685·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Irinotecan liposoma. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Irinotecan liposoma compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Irinotecan liposoma. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dai, Guanghai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDai, Guanghai

Irinotecan liposoma

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Bevacizumab1 trial

References

Drug Info

Quick Facts

Related News